Trevogrumab Prevents 70% of Muscle Loss on GLP-1s! EASD 2026

The Downsized — Trevogrumab Prevents 70% of Muscle Loss on GLP-1s! EASD 2026

Channel: DOWNSIZED · Our label: Patient-experience channel — GLP-1 journey, daily · Source: youtube.com/watch?v=zfFlhXB8EvM

What this video covers

From the press, from social media, even from your nosy neighbor. At the EASD conference in Milan, researchers showed a drug that stopped most of that muscle loss and explained what was going on. Now, the real question, does keeping the muscle make you any stronger? My name is Christopher Durham and welcome to The Downsized.

Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.

Key points, in the speaker’s own framing

• We’re not doctors and nothing here is medical advice.
• This is episode 3 of our 10-part series on the biggest obesity research from EASD 2026, the European Association for the Study of Diabetes meeting held in Milan from September 28th through October 2nd.
• The trial we’re covering today shows what that looks like.
• In Lilly’s SURMOUNT-1 trial, a body scan sub study found people lost about three times as much fat as lean mass.
• Trevogrumab is not currently approved by the FDA, so it’s still in trials.
• That has to come before the big phase three trials the the would need, and there’s no guarantee of approval.

Read next

• GLP-1 class — more videos
• Semaglutide — more videos
• Tirzepatide — more videos
• Retatrutide — more videos
• All videos from this channel

Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.